fy17 dmdrp program announcements and general application instructions for the following award mechanisms are posted on grants.gov.

as directed by the office of the assistant secretary of defense for health affairs, the defense health agency (dha) j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

all applications for the fy17 dmdrp funding opportunities are required to address at least one of the following focus areas:

• cardiac studies, including identifying mechanisms of pathology and therapeutic interventions
• clinical studies, novel interventions, and drug and biologic delivery technologies designed to improve clinical care and quality of life in areas such as:

○        cognitive function

○        endocrinology

○        gastrointestinal issues

○        immunology

○        orthopaedics

○        psychosocial issues

○        pulmonology (including sleep-focused studies)

○        skeletal muscle

• assessment of clinical trial tools and outcome measures, such as:

○        discovery and qualification of pharmacodynamic, prognostic, and predictive biomarkers

○        novel clinical outcome assessments

○        patient-centered outcomes, e.g., quality of life, activities of daily living

○        potential surrogate markers

• extension or expansion of existing preclinical translational data in support of a specific therapeutic development path (including drug exposure, independent replication, and comparative studies)

investigator-initiated research award – preapplication due july 19, 2017

principal investigator:  must be an independent investigator at or above the level of assistant professor (or equivalent).
optional nested resident or medical student trainee: resident trainee must be enrolled in an accredited residency program.  medical student trainee must be enrolled in a nationally accredited (or equivalent) medical school.  trainees must be able to devote a minimum of 40% level of effort.

optional multidiscipline collaborator:  must be an independent investigator at or above the level of assistant professor (or equivalent).

·         supports translational research that will have an impact on improving the function, quality of life, and/or extending the lifespan for all individuals with duchenne.

·         supports translational research that will accelerate the movement of promising new ideas in duchenne research in clinical applications.

·         optional multidiscipline collaboration: supports projects that include multi-disciplinary collaborations including, but not limited to, the following: immunology, nanotechnology, or orthopaedics. applications that include a multidiscipline collaborator who meets criteria identified in the program announcement/funding opportunity may apply for a higher level of funding.

·         clinical trials are allowed.

• preliminary data are required.

·         maximum funding of $600,000 for direct costs (plus indirect costs).

·         maximum period of performance is 3 years.

·         nested traineeship: additional maximum of $50,000 for residents or $30,000 for medical 世界杯2022赛程表淘汰赛 in direct costs (plus indirect costs) over a one-year period of performance.

optional multidiscipline collaboration:  additional maximum of $150,000 in direct costs over the 3-year period of performance.

fy17 prorp program announcements and general application instructions for the following award mechanisms are posted on grants.gov. 

as directed by the office of the assistant secretary of defense for health affairs, the defense health agency (dha), j9 research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

focus areas:  the prorp will only consider applications that specifically address the critical needs of the orthopaedic research community in one or more of the fy17 focus areas.  the prorp will solicit research applications that address at least one of the following fy17 focus areas (note that focus area requirements vary by award mechanism):

surgical care focus areas:

·         peripheral nerve injuries:  treatment strategies to improve outcomes from segmental peripheral nerve defects of motor and mixed (motor and sensory) peripheral nerve damage from crush or complete injury.

·         prevention of heterotopic ossification:  techniques to retard or prevent the development of human post-traumatic heterotopic ossification in the upper extremity.

·         volumetric muscle loss:  techniques to regenerate functional, innervated muscle units in treatment of volumetric muscle loss.

·         extremity fractures:  strategies to optimize patient outcomes after extremity fracture (i.e., time to begin rehabilitation, weight-bearing strategy, etc.)

·         pelvic ring injuries:  treatment strategies to improve outcomes of complex pelvic ring injuries.

·         compartment syndrome:  strategies to improve current diagnoses for compartment syndrome.

·         gaps in clinical practice guidelines:  address gaps in current orthopaedic clinical practice guidelines (cpg) and recommendations (http://www.usaisr.amedd.army.mil/cpgs.html).  applications under this focus area must specify which orthopaedically relevant cpg their application is intended to support.  applicants should also highlight the expected impact of their research on orthopaedic clinical practice.

·         surgical techniques to optimize gait:  validate surgical techniques to optimize gait efficiency and outcomes for patients with amputation or limb salvage.

·         soft tissue trauma:  strategies to develop and/or identify musculoskeletal extremity soft tissue trauma treatments optimizing return to duty, work, or reintegration.

·         osteoarthritis:  treatment strategies involving large animal studies, clinical research, or clinical trials to improve outcomes of osteoarthritis and/or post-traumatic osteoarthritis.

rehabilitation focus areas:

·         post-operative pain management:  develop and/or validate strategies for post-operative pain management following orthopaedic trauma that minimize or eliminate opioid use.  the primary outcome measures should relate to rehabilitation endpoints and not focus solely on pain scores.

·         prosthetic and/or orthotic device function:  development and optimization of novel, innovative technologies to improve prosthetic and/or orthotic device function and durability, including intuitive efferent (motor) and afferent (sensory) user interfaces and considerations for interoperability.

·         secondary physical health effects:  techniques or technologies that improve prediction, identification, and reduction of secondary physical health effects (e.g., obesity, arthrosis, osteoporosis, cardiovascular disease) following severe/high-energy traumatic neuromusculoskeletal non-spinal cord injury.  the focus should be on injuries sustained between the ages of 18-50 and secondary physical health effects that develop within 5 years of injury.

·         physical or occupational therapy:  development and/or validation of optimal physical or occupational therapy treatment strategies and sequence of progression throughout the rehabilitation continuum to maximize functional outcomes following severe neuromusculoskeletal injury, excluding central nervous system.  examples include optimal timing, frequency, duration, and intensity of rehabilitation interventions.

·         barriers to successful therapy outcomes:  identify, quantify, and stratify confounding treatable factors (e.g., pain, sleep, nutrition, compliance, etc.) that inhibit or delay optimal orthopaedic rehabilitation outcomes.

·         rehabilitation outcomes:  development and/or validation of standardized measures to objectively assess and improve rehabilitation outcomes, including multi-extremity trauma and/or psychosocial resiliency and reintegration, following neuromusculoskeletal injury.

·         osteoarthritis:  development and/or validation of optimal physical or occupational therapy treatment strategies to improve outcomes of osteoarthritis and/or post-traumatic osteoarthritis.

applied research award – preapplication due july 12, 2017

independent investigators at all academic levels (or equivalent) are eligible to submit applications.

• pre-application is required; full application submission is by invitation only.
• supports applied research applications focused on advancing optimal treatment and restoration of function for military personnel with musculoskeletal injuries sustained during combat or combat-related activities.
• applications must address one and only one of the fy17 prorp focus areas.
• proposed research should be supported by preliminary data and have the potential to make significant advancements toward clinical translation.
• applications are highly encouraged to include large animal studies in their research plan, where appropriate.

clinical trials are not allowed under this award mechanism

·        maximum funding of $750,000 for total costs

·        maximum period of performance is 3 years

·        all direct and indirect costs of any subaward (subgrant or subcontract) must be included in the total direct costs of the primary award.

the applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 3 years.

clinical trial award – preapplication due july 12, 2017

independent investigators at all academic levels (or equivalent) are eligible to submit applications.

• pre-application is required; full application submission is by invitation only.
• supports the rapid implementation of clinical trials with the potential to have a major impact on military combat-related orthopaedic injuries, or non-battle injuries that significantly impact unit readiness and return-to-duty/work rates
• applications must address one and only one of the fy17 prorp focus areas.
• funding must support a clinical trial and may not be used for preclinical research studies.
• collaboration with military researchers and clinicians is encouraged.
• studies that include active duty military or veteran participants as all or a portion of the study population will be considered.

investigational new drug or investigational device exemption applications, if needed, should be submitted to the food and drug administration within 6 months of the award date.

·        maximum funding of $3 million (m) for direct costs (plus indirect costs)

·        maximum period of performance is 4 years.

·        all direct and indirect costs of any subaward (subgrant or subcontract) must be included in the total direct costs of the primary award.

the applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 4 years.

integrated clinical trial award – preapplication due july 12, 2017

independent investigators at all academic levels (or equivalent) are eligible to submit applications.

• pre-application is required; full application submission is by invitation only.
• supports the rapid implementation of inter-disciplinary clinical trials with the potential to have a major impact on military combat-related orthopaedic injuries, or non-battle injuries that significantly impact unit readiness and return-to-duty/work
• applications must address at least two (minimum of one surgical care and one rehabilitation) and a maximum of four of the fy17 prorp focus areas.
• required qualified collaborator: to encourage meaningful and productive multidisciplinary collaborations, there must be at least one investigator with rehabilitation expertise and at least one clinician who specializes in orthopaedic or trauma care.
• collaboration with military researchers and clinicians is encouraged.
• studies that include active duty military or veteran participants as all or a portion of the study population will be considered.

investigational new drug or investigational device exemption applications, if needed, should be submitted to the food and drug administration within 6 months of the award date.

·        maximum funding of $4.5m for direct costs (plus indirect costs)

·        maximum period of performance is 4 years.

·        all direct and indirect costs of any subaward (subgrant or subcontract) must be included in the total direct costs of the primary award.

the applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 4 years.

clinical translational research award – preapplication due july 12, 2017

independent investigators at all academic levels (or equivalent) are eligible to submit applications.

• pre-application is required; full application submission is by invitation only.
• supports research that evaluates the effectiveness of health care practices and/or interventions with potential to impact the standard of care and contribute to evidence-based guidelines for the evaluation and care of military or veteran amputee and/or limb salvage patients.
• applications must address one and only one of the fy17 prorp rehabilitation focus areas.
• funding must support clinical research studies involving humans.
• preliminary or published data relevant to the proposed research project are required.
• collaboration with military researchers and clinicians is encouraged.
• studies that include active duty military or veteran participants as all or a portion of the study population will be considered.

investigational new drug or investigational device exemption applications, if needed, should be submitted to the food and drug administration within 6 months of the award date.

·        maximum funding of $2m for direct costs (plus indirect costs)

·        maximum period of performance is 4 years.

·        all direct and indirect costs of any subaward (subgrant or subcontract) must be included in the total direct costs of the primary award.

the applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 4 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism can also be found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

applications must be submitted through the federal government’s single-entry portal, grants.gov.  for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the prorp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

point of contact:

help desk

301-682-5507

help@ebrap.org

fy17 pcrp program announcements and general application instructions for the following award mechanisms are posted on grants.gov. 

as directed by the office of the assistant secretary of defense for health affairs, the defense health agency’s research and development directorate manages the defense health program’s research, development, test, and evaluation appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

important:  the pcrp’s fy17 mission is to find and fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of men experiencing the impact of the disease.  as such, the pcrp seeks to focus applications and direct funding on four overarching challenges and seven focus areas to address critical needs in prostate cancer research and clinical management.  applicants are strongly encouraged to submit research that addresses one or more of the overarching challenges and focus areas.

overarching challenges:  (1) distinguish aggressive from indolent disease in men newly diagnosed with prostate cancer.  (2) develop strategies to prevent progression to lethal prostate cancer.  (3) develop effective treatments and address mechanisms of resistance for men with high-risk or metastatic prostate cancer.  (4) develop strategies to optimize the physical and mental health of men with prostate cancer.

focus areas:  (1) precision medicine, screening, and surveillance; (2) imaging and targeted radionuclide therapy; (3) therapy and mechanisms of resistance and response; (4) survivorship, including psychosocial impact on the patient and family; (5) tumor and microenvironment biology; (6) data science and analytics; and (7) population science

clinical consortium award – letter of intent due august 24, 2017

·         independent investigators at or above the level of assistant professor (or equivalent)

·         supports the development of a consortium that will facilitate the rapid execution of collaborative phase ii or phase i/ii clinical trials that will bring to market high-impact, novel therapeutic interventions that will ultimately and significantly decrease the impact of prostate cancer.

·         funds may not be used for research or development of clinical protocols.

·         trials that incorporate investigations of biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of prostate cancer are encouraged.

·         one coordinating center and 2 clinical research sites will be selected and will be jointly responsible for proposing, selecting, and conducting trials.

·         sites must provide plans for accruing patients from populations disproportionately affected by prostate cancer.

·         the consortium is expected to achieve financial self-sufficiency, such that operations can continue after the award ends.

coordinating center:

·         maximum funding of $3.6 million (m) for direct costs (plus indirect costs)

·         maximum period of performance is 3 years

clinical sites:

·         maximum funding of $600 thousand ($600k) for direct costs (plus indirect costs)

·         maximum period of performance is 3 years

impact award – preapplication due july 7, 2017

·         independent investigators at or above the level of assistant professor (or equivalent)

·         preproposal is required; application submission is by invitation only.

·      supports high-impact, potentially high-risk studies (including clinical trials) that address a central question or problem in prostate cancer.  as such, the primary emphasis of this mechanism is on impact(s).

·      the potential impact of the research is expected to be near-term and must be significant and go beyond an incremental advancement.

·      proposed projects may include basic, translational, or clinical research, including clinical trials, but must demonstrate clinical relevance.

·      preliminary data to support feasibility are required.

partnering principal investigator (pi) option:

·      provides a higher level of funding to support synergistic partnerships between two or three independent investigators collaborating on a single application.

·      pis are expected to demonstrate within the application the synergistic components that will significantly advance the project, such that the research outcomes could not otherwise be accomplished through the independent efforts of a single pi.

·         allows individual awards to multiple sites (maximum of three sites in total), provided the combined direct costs for all sites do not exceed the $2m maximum.

individual pis:

·         maximum funding of $750k for direct costs (plus indirect costs)

·         maximum period of performance is 3 years

partnering pi option:

·         maximum funding of $2m for direct costs (plus indirect costs)

·         maximum period of performance is 3 years

health disparity research award – preapplication due july 7, 2017

established investigators:  independent investigators at or above the level of assistant professor (or equivalent);

or

new investigators:  investigators that meet the following criteria at the application submission deadline date:

·         have the freedom to pursue individual aims without formal mentorship

·         have not previously received a pcrp health disparity research award and/or idea development award

·         have either completed at least 3 years of postdoctoral training or fellowship or are within 5 years of having begun first independent faculty position (or equivalent)

preproposal is required; application submission is by invitation only.

·      supports new ideas for prostate cancer research that have the potential to make an important contribution to reducing and ultimately eliminating disparities in prostate cancer incidence, morbidity, and mortality. 

·      preliminary data are encouraged, but not required.

·         new investigator option supports applicants early in their faculty appointments or in the process of developing independent research careers.

·         qualified collaborator option supports a higher level of funding for pis who include a collaborator that significantly contributes (provides 10% or greater level of effort, as well as both intellectual input and research resources) to the research project, such that it could not otherwise be accomplished.

·         nested young investigator option supports predoctoral and postdoctoral training, nested within the overall proposed project, for individuals committed to pursuing careers as independent investigators in prostate cancer health disparity research.

·         maximum funding of $450k for direct costs (plus indirect costs)

·         if applying for the qualified collaborator option, maximum funding of $600k for direct costs (plus indirect costs)

·         maximum period of performance is 3 years

·         additional funds can be requested if including the nested young investigator option

idea development award – preapplication due july 14, 2017

established investigators:  independent investigators at or above the level of assistant professor (or equivalent);

or

new investigators:  investigators that meet the following criteria at the application submission deadline date:

·         have the freedom to pursue individual aims without formal mentorship

·         have not previously received a pcrp idea development award

·         have either completed at least 3 years of postdoctoral training or fellowship or are within 5 years of having begun first independent faculty position (or equivalent)

preproposal is required; application submission is by invitation only.

·      supports new ideas that represent innovative, high-risk/high-gain approaches to prostate cancer research and have the potential to make an important contribution to eliminating death and enhancing the well-being of men with prostate cancer.

·      emphasis is equally placed on innovation and impact.

·      preliminary data are encouraged, but not required.

·      clinical trials are not allowed.

·      new investigator option supports applicants early in their faculty appointments or in the process of developing independent research careers.

·      partnering pi option:

o  provides a higher level of funding to support synergistic partnerships between two or three independent established investigators collaborating on a single application.

o  pis are expected to demonstrate within the application the synergistic components that will significantly advance the project, such that the research outcomes could not otherwise be accomplished through the independent efforts of a single pi.

·         allows individual awards to multiple sites (maximum of three sites in total), provided the combined direct costs for all sites do not exceed the $1m maximum.

established pis:

·     maximum funding of $600k for direct costs (plus indirect costs)

new investigator option:

·     maximum funding of $375k for direct costs (plus indirect costs)

partnering pi option:

·     maximum funding of $1m for direct costs (plus indirect costs)

maximum period of performance is 3 years

physician research award – letter of intent due july 27, 2017

at the time of application submission, the pi must be either:

in the last year of an accredited medical residency or medical fellowship program;

or

within 3 years of having initiated an appointment as instructor, assistant professor, or equivalent

·      supports mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research.

·      pis must demonstrate a commitment to a career at the forefront of prostate cancer research and clinical practice.

·      pis must have a designated mentor with an established research program in prostate cancer.

·      institutions must provide at least 40% protection of pi’s time for research.

·       projects that focus on basic research are highly encouraged.

·     maximum funding of $520k for direct costs (plus indirect costs)

·       maximum period of performance is 4 years

early investigator research award – letter of intent due july 27, 2017

by march 31, 2018

postdoctoral ph.d. or m.d. pis:

·    must have successfully defended a doctoral thesis or possess an m.d. degree and

·       have 3 years or less of postdoctoral fellowship

·      supports research opportunities focused on prostate cancer for individuals in the early stages of their careers.

·       pis must have a designated mentor who is an experienced prostate cancer researcher.

·     maximum of $200k for direct costs (plus indirect costs)

·       maximum period of performance is 2 years

prostate cancer pathology resource network award

independent investigators at or above the level of assistant professor (or equivalent) with access to the appropriate facilities

·       provides infrastructure support for the development and maintenance of a prostate cancer biorepository through a collaborative network across multiple institutions that will facilitate the collection, processing, annotation, storage, and distribution of high-quality human prostate cancer biospecimens.

·       major emphasis for biospecimen collection must be placed on the acquisition and distribution of biospecimens in limited supply in the prostate cancer research community.

·       each application must include one coordinating center and three to five pathology resource sites (including one at the coordinating center), all of which will be jointly responsible for development of the biospecimen repository.

·       sites must provide plans for quality assurance, bioinformatics and data management, and ethical and regulatory issues

·       encourages submissions from investigators with enhanced skills in human biospecimen procurement, human tissue repositories, distribution, and working within a collaborative consortium-type network of multiple institutions.

·      maximum funding of $3.6m for direct costs (plus indirect costs)

·       maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions that will be available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

applications must be submitted through the federal government’s single-entry portal, grants.gov.  for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the pcrp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

point of contact:

cdmrp help desk

301-682-5507

help@ebrap.org

fy17 prmrp program announcements and general application instructions for the following award mechanisms are posted on grants.gov.  

as directed by the office of the assistant secretary of defense for health affairs, the defense health agency (dha) j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation. the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

congressionally directed topic areas.  all applications submitted to the prmrp must address at least one of the fy17 prmrp congressionally directed topic areas.  as of the release date of this pre-announcement, the fy17 prmrp topic areas have not been finalized.  this pre-announcement should not be construed as an obligation by the government to include any of these topic areas or others in the fy17 prmrp.  the potential fy17 prmrp topic areas are:

military relevance:  relevance to the healthcare needs of the military service members, veterans, and beneficiaries is a key feature of each fy17 prmrp award mechanism.

clinical trial award- preapplication due july 20, 2017

·         assistant professor level or above (or equivalent)

·         preproposal submission is required; application submission is by invitation only.

·         supports the rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the topic area(s) of interest.

·         proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.

·         investigational new drug or investigational device exemption applications, if needed, should be submitted to the food and drug administration by the prmrp grants.gov application submission deadline.

·         funding limit not defined; requested funding must be appropriate for the scope of work proposed

·         maximum period of performance is 4 years

discovery award – letter of intent due july 19, 2017

·         all investigators

·         supports the exploration of a highly innovative new concept or untested theory.

·         not intended to support the logical progression of an already established line of questioning.

·         clinical trials will not be funded.

·         reviewers will be blinded to the identity of the principal investigator (pi), collaborators, and their organization(s).

·         maximum of $200,000for direct costs (plus indirect costs)

·         maximum period of performance is 18 months

focused program award – preapplication due july 20, 2017

·         full professor level or above (or equivalent)

·         preproposal submission is required; application submission is by invitation only.

·         supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal.

·         projects should work together to answer critical questions, resolve differing hypotheses, and translate laboratory findings to clinical applications.

·         projects may range from exploratory/ hypothesis-developing through small-scale clinical trials that together will address the overarching goal/question.

·         research team of highly qualified, multidisciplinary project leaders should be led by a pi with demonstrated success in directing large, focused projects.

·         maximum of $10millionfor total costs (includes direct and indirect costs)

·         maximum period of performance is 4 years

investigator-initiatedresearchaward – preapplication due july 13, 2017

• assistant professor level or above (or equivalent)

·         preproposal submission is required; application submission is by invitation only.

·         supports research that will make an original and important contribution to the field of research or patient care in the topic area(s) of interest.

·         partnering pi option available.

• clinical trials will not be funded.

·         maximum of $1.2millionfor direct costs (plus indirect costs)

·         maximum of $1.5millionfor direct costs (plus indirect costs) for applications including a partnering pi option

• maximum period of performance is 3 years

technology/therapeuticdevelopmentaward – preapplication due july 13, 2017

• assistant professor level or above (or equivalent)

·         supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, or quality of  life.

·         product-oriented (e.g., device, drug, clinical guidelines). the product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.

·         clinical trials will not be funded.

• preproposal submission is required; application submission is by invitation only.

·         maximum of $3.0millionfor direct costs (plus indirect costs)

·           maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website. the application package containing the required forms for each award mechanism can also be found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.

applications must be submitted through the federal government’s single-entry portal, grants.gov. for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the prmrp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

the responsive grants program enables the law foundation of ontario to fund ideas generated by nonprofit community groups to improve access to justice. these grants have provided seed funding for hundreds of innovative projects across ontario.

the law foundation of ontario invites applications from nonprofit organizations across canada to the access to justice fund (atjf) in the area of family law, including child protection. family law, including child protection, is an important area of focus for the foundation because many people experiencing family problems struggle to use the law to improve their lives and address those problems. this is a unique opportunity to further access to justice for families through innovative projects.

• family law major grants: next letter of intent due date is october 2, 2017.
  • family law grant application form and instructions

the law foundation of ontario invites applications from nonprofit organizations across canada to the access to justice fund (atjf) in the area of family law, including child protection. family law, including child protection, is an important area of focus for the foundation because many people experiencing family problems struggle to use the law to improve their lives and address those problems. this is a unique opportunity to further access to justice for families through innovative projects.

• small grants of up to $15,000

the discovery grants program supports ongoing programs of research (with long-term goals) rather than a single short-term project or collection of projects. these grants recognize the creativity and innovation that are at the heart of all research advances. discovery grants are considered ‘grants in aid’ of research as they provide long term operating funds to support the costs of a research program. as a grant in aid of research, discovery grants are not meant to support the full costs of a research program and they can facilitate access to funding from other programs. nserc recognizes that, while being of a grant in aid nature, discovery grants must be sufficient to support a program of quality research that can have a meaningful impact on the field of study.

catalyst grant – in this request for proposals we are seeking to fund exploratory projects the successful completion of which would provide preliminary data to support other funding applications either to glyconet, the canadian institutes of health research or a private disease-specific foundation.

potential applicants must register by email to karli buckle (kbuckle@ualberta.ca) by friday, july 14, 2017. please provide the project title, anticipated budget request, and list of investigators involved in the project. this information is not binding and can change when the application is submitted. upon registration, applicants will receive instructions for completing the application. funding is anticipated to begin on january 1, 2018.

applications must be submitted by midnight pst monday, august 14, 2017. proposals received after this deadline will not be considered.

collaborative team grant – a key goal of glyconet is to support research projects that are multi-disciplinary, as defined by the nce program. accordingly, this request for proposals seeks to fund projects that are broad in scope and that involve at least two, and ideally more, research groups in different disciplines.

potential applicants must register by email to karli buckle (kbuckle@ualberta.ca) by friday, july 14, 2017. please provide the project title, anticipated budget request, a 500-word (maximum) summary of the project, and list of investigators involved in the project. this information can be modified when the application is submitted although the overall focus must remain the same. upon registration, applicants will receive instructions for completing the application. funding is anticipated to begin on january 1, 2018.